Cargando…

Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatments over the last 10 years, with even increasing indications in many neoplasms. Non-small cell lung cancer (NSCLC) is considered highly immunogenic, and ICIs have found a wide set of applications in this area, in both early and ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Gemelli, Maria, Noonan, Douglas M., Carlini, Valentina, Pelosi, Giuseppe, Barberis, Massimo, Ricotta, Riccardo, Albini, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194506/
https://www.ncbi.nlm.nih.gov/pubmed/35712510
http://dx.doi.org/10.3389/fonc.2022.886440
_version_ 1784726743660101632
author Gemelli, Maria
Noonan, Douglas M.
Carlini, Valentina
Pelosi, Giuseppe
Barberis, Massimo
Ricotta, Riccardo
Albini, Adriana
author_facet Gemelli, Maria
Noonan, Douglas M.
Carlini, Valentina
Pelosi, Giuseppe
Barberis, Massimo
Ricotta, Riccardo
Albini, Adriana
author_sort Gemelli, Maria
collection PubMed
description Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatments over the last 10 years, with even increasing indications in many neoplasms. Non-small cell lung cancer (NSCLC) is considered highly immunogenic, and ICIs have found a wide set of applications in this area, in both early and advanced lines of treatment, significantly changing the prognosis of these patients. Unfortunately, not all patients can benefit from the treatment, and resistance to ICIs can develop at any time. In addition to T lymphocytes, which are the major target, a variety of other cells present in the tumor microenvironment (TME) act in a complex cross-talk between tumor, stromal, and immune cells. An imbalance between activating and inhibitory signals can shift TME from an “anti-” to a “pro-tumorigenic” phenotype and vice versa. Natural killer cells (NKs) are able to recognize cancer cells, based on MHC I (self and non-self) and independently from antigen presentation. They represent an important link between innate and adaptive immune responses. Little data are available about the role of pro-inflammatory NKs in NSCLC and how they can influence the response to ICIs. NKs express several ligands of the checkpoint family, such as PD-1, TIGIT, TIM-3, LAG3, CD96, IL1R8, and NKG2A. We and others have shown that TME can also shape NKs, converting them into a pro-tumoral, pro-angiogenic “nurturing” phenotype through “decidualization.” The features of these NKs include expression of CD56, CD9, CD49a, and CXCR3; low CD16; and poor cytotoxicity. During ICI therapy, tumor-infiltrating or associated NKs can respond to the inhibitors or counteract the effect by acting as pro-inflammatory. There is a growing interest in NKs as a promising therapeutic target, as a basis for adoptive therapy and chimeric antigen receptor (CAR)-NK technology. In this review, we analyzed current evidence on NK function in NSCLC, focusing on their possible influence in response to ICI treatment and resistance development, addressing their prognostic and predictive roles and the rationale for exploiting NKs as a tool to overcome resistance in NSCLC, and envisaging a way to repolarize decidual NK (dNK)-like cells in lung cancer.
format Online
Article
Text
id pubmed-9194506
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91945062022-06-15 Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer Gemelli, Maria Noonan, Douglas M. Carlini, Valentina Pelosi, Giuseppe Barberis, Massimo Ricotta, Riccardo Albini, Adriana Front Oncol Oncology Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatments over the last 10 years, with even increasing indications in many neoplasms. Non-small cell lung cancer (NSCLC) is considered highly immunogenic, and ICIs have found a wide set of applications in this area, in both early and advanced lines of treatment, significantly changing the prognosis of these patients. Unfortunately, not all patients can benefit from the treatment, and resistance to ICIs can develop at any time. In addition to T lymphocytes, which are the major target, a variety of other cells present in the tumor microenvironment (TME) act in a complex cross-talk between tumor, stromal, and immune cells. An imbalance between activating and inhibitory signals can shift TME from an “anti-” to a “pro-tumorigenic” phenotype and vice versa. Natural killer cells (NKs) are able to recognize cancer cells, based on MHC I (self and non-self) and independently from antigen presentation. They represent an important link between innate and adaptive immune responses. Little data are available about the role of pro-inflammatory NKs in NSCLC and how they can influence the response to ICIs. NKs express several ligands of the checkpoint family, such as PD-1, TIGIT, TIM-3, LAG3, CD96, IL1R8, and NKG2A. We and others have shown that TME can also shape NKs, converting them into a pro-tumoral, pro-angiogenic “nurturing” phenotype through “decidualization.” The features of these NKs include expression of CD56, CD9, CD49a, and CXCR3; low CD16; and poor cytotoxicity. During ICI therapy, tumor-infiltrating or associated NKs can respond to the inhibitors or counteract the effect by acting as pro-inflammatory. There is a growing interest in NKs as a promising therapeutic target, as a basis for adoptive therapy and chimeric antigen receptor (CAR)-NK technology. In this review, we analyzed current evidence on NK function in NSCLC, focusing on their possible influence in response to ICI treatment and resistance development, addressing their prognostic and predictive roles and the rationale for exploiting NKs as a tool to overcome resistance in NSCLC, and envisaging a way to repolarize decidual NK (dNK)-like cells in lung cancer. Frontiers Media S.A. 2022-05-31 /pmc/articles/PMC9194506/ /pubmed/35712510 http://dx.doi.org/10.3389/fonc.2022.886440 Text en Copyright © 2022 Gemelli, Noonan, Carlini, Pelosi, Barberis, Ricotta and Albini https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gemelli, Maria
Noonan, Douglas M.
Carlini, Valentina
Pelosi, Giuseppe
Barberis, Massimo
Ricotta, Riccardo
Albini, Adriana
Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
title Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
title_full Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
title_fullStr Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
title_full_unstemmed Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
title_short Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
title_sort overcoming resistance to checkpoint inhibitors: natural killer cells in non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194506/
https://www.ncbi.nlm.nih.gov/pubmed/35712510
http://dx.doi.org/10.3389/fonc.2022.886440
work_keys_str_mv AT gemellimaria overcomingresistancetocheckpointinhibitorsnaturalkillercellsinnonsmallcelllungcancer
AT noonandouglasm overcomingresistancetocheckpointinhibitorsnaturalkillercellsinnonsmallcelllungcancer
AT carlinivalentina overcomingresistancetocheckpointinhibitorsnaturalkillercellsinnonsmallcelllungcancer
AT pelosigiuseppe overcomingresistancetocheckpointinhibitorsnaturalkillercellsinnonsmallcelllungcancer
AT barberismassimo overcomingresistancetocheckpointinhibitorsnaturalkillercellsinnonsmallcelllungcancer
AT ricottariccardo overcomingresistancetocheckpointinhibitorsnaturalkillercellsinnonsmallcelllungcancer
AT albiniadriana overcomingresistancetocheckpointinhibitorsnaturalkillercellsinnonsmallcelllungcancer